Pharma Reviews: Tax cuts to jazz up Q2 bottomlines of Nifty50 even as revenue growth slows

Management outlook on performance of specialty drugs portfolio, volume growth in Indian pharma market and update on regulatory compliance will ...
Read more: Tax cuts to jazz up Q2 bottomlines of Nifty50 even as revenue growth slows